Clinical Trial Update: Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients [Phase 1]

View source ↗

Summary

The update indicates completion of a Phase 1 trial evaluating repeated subcutaneous administration of ABvac40 in patients with mild to moderate Alzheimer's dise…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• ABvac40

Snippet

Sponsor: Araclon Biotech S.L. | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED